Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Investigate the Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

NCT04401800 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04401800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04401800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Investigate the Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
September 4, 2020
Completion date
February 18, 2024
Enrollment
64 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, metastatic hepatocellular carcinoma, unresectable hepatocellular carcinoma